OBJECTIVE: To probe into the clinical efficacy of empagliflozin combined with insulin aspart in the treatment of type 2 diabetes poorly controlled by insulin alone. METHODS: A total of 180 patients with type 2 diabetes poorly controlled by insulin alone admitted into the hospital from Jan. 2018 to Oct. 2020 were selected as research subjects

which were selected and divided into the control group and the observation group via random number table

with 90 cases in each group. The control group was treated with insulin aspart alone

while the observation group was given empagliflozin on the basis of control group. The changes of blood glucose

blood lipid

blood pressure

average daily insulin dosage and other indicators were compared between two groups before and after treatment. RESULTS: The indicators of blood glucose（glycosylated hemoglobin

2 h postprandial blood glucose and fasting blood glucose） in the observation groups after treatment were significantly lower than those of the control group; in terms of blood lipid indicators

the triglycerides was significantly lower than that in the control group

while the high density lipoprotein cholesterol was significantly higher than that in the control group; in terms of blood pressure indicators

the systolic blood pressure and diastolic blood pressure were significantly lower than those in the control group; and the insulin dosage was significantly less than that in the control group

with statistically significant differences（P<0.05）. The incidence of adverse drug reactions in the observation group was 8.9%（8/90）

significantly lower than 13.3%（12/90） in the control group

with statistically significant differences（P<0.05）. CONCLUSIONS: Empagliflozin combined with insulin aspart has better blood glucose control effect on type 2 diabetic patients with poorly controlled by insulin alone

which can effectively control patients’ blood pressure and reduce insulin dosage.